Immunovant

PriceImmunovant

IMVT

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Historical stock price chart and annual return over the past years

14%

5 years

% Total

IMVT
3%

5 years

Annual Return

IMVT